A nationwide population-based study. Pai-Feng Hsu M.D. Shao-Yuan Chuang PhD

Size: px
Start display at page:

Download "A nationwide population-based study. Pai-Feng Hsu M.D. Shao-Yuan Chuang PhD"

Transcription

1 The Association of Clinical Symptomatic Hypoglycemia with Cardiovascular Events and Total Death in Type 2 Diabetes Mellitus A nationwide population-based study Pai-Feng Hsu M.D. Shao-Yuan Chuang PhD Taipei Veteran General Hospital, Taiwan National Yang-Ming University National Health Research Institutes, Taiwan

2 Declaration of Conflicts of Interest None

3 Hypoglycemia in type 2 diabetes Hypoglycemia symptoms are common in type 2 diabetes Incidence of mild episodes is 2-10 per patient/year; severe episodes is per patient/year 1 Associated with: Reduced quality of life Reduced treatment satisfaction Reduced therapy adherence More common at HbA1c < 7% Increased long term morbidity and mortality? 1. UK hypoglycaemia study group. Diabetologia. 2007;50:

4 Immediate Cardiovascular Complications of Severe Hypoglycemia Increased Risk of Cardiac Arrhythmia 1 Abnormal prolonged cardiac repolarization QTc Sudden death Increased Risk of Ischemic Heart 2 Sympathetic surge Destabilized atherosclerotic plaque Increased platelet aggregation 1. Landstedt-Hallin L et al. J Intern Med. 1999;246: Wright RJ, et al. Diabetes Metab Res Rev. 2008; 24:

5 Serious Clinical Outcomes After a Hypoglycemic Episode in Hospitalized Patients with Diabetes Study No of Subjects Comparison Groups Time of Outcome All Cause Death HR (95% CI) CV Death HR (95% CI) Svensson et al (2005) Kosiborod et al (2008) 684 Hypo vs Norm in acute MI admission 2 years 1.93 ( ) 4916 Hypo vs Norm in hospitalization for acute MI DIGAMI-2 trial 1253 Symptomatic hypoglycemia vs no hypoglycemia during the first 24 h of hospitalization for acute MI CREATE-ECLA and OASIS-6 trials 5440 Hypo vs norm on admission for acute MI Hypo vs norm 24 h after an acute MI Length of hospitalization NA 6.5* NA 2.1 years 1.09 ( ) 30 d 2.13 ( ) 30 d 1.58 ( ) *Adjusted odds ratio in the subgroup of patients with diabetes was estimated from a graph ( ) NA NA Natalia Yakubovich et al, Circulation 2011, 123:

6 Increased Risk of Hypoglycemic Episodes by Aggressive Intervention dose not Necessarily Increase the Risk of Coronary Heart Disease Events Meta-analysis: impact of intensive glucose control on coronary heart disease* events Intensive treatment/standard treatment Participants Events Odds ratio (95% CI) Odds ratio (95% CI) UKPDS 3,071/ / ( ) PROactive 2,605/ / ( ) ADVANCE 5,571/5, / ( ) VADT 892/899 77/ ( ) ACCORD 5,128/ / ( ) Overall 17,267/15,773 1,182/1, ( ) 0.6 Intensive treatment better Standard treatment better *Included non-fatal myocardial infarction and death from all cardiac mortality. Ray KK, et al. Lancet 2009; 373:

7 Severe Hypoglycemia is Strongly Associated with Increased Risks of Adverse Clinical Outcomes Events 11,140 patients with type 2 diabetes participated in ADVANCE study Severe Hypoglycemia n=231 No Severe Hypoglycemia n=10,909 No of patients with events (%) Hazard Ratio* (95% CI) Hazard Ratio* (95% CI) Macro vascular 33 (15.9) 1114 (10.2) 3.53 ( ) Micro vascular 24 (11.5) 1107 (10.1) 2.19 ( ) Total Death 45 (19.5) 986 (9.0) 3.27 ( ) CVD 22 (9.5) 520 (4.8) 3.79 ( ) Non-CVD 23 (10.0) 466 (4.3) 2.80 ( ) *All in adjusted models Zoungas et al, NEJM 2010;363;

8 Gaps The impact of clinical outpatient hypoglycemic episodes in type 2 diabetes mellitus patients on long term cardiovascular outcome remains unclear. Whether the hypoglycemia episodes are a risk factor or marker for future cardiovascular events remains debatable.

9 Objective To investigate the associations of outpatient and inhospital hypoglycemic episodes with long term outcome, including cardiovascular events and allcause mortality in treated type 2 diabetes patients. To explore the temporal relationship between hypoglycemia episodes and events.

10 Research Design and Methods The study population, identified from the one million patients in the nationally representative sample dataset (National Health Insurance Research Database) released by the Taiwan National Health Research Institutes during A total of 77,611 newly diagnosed diabetes were identified with more than 3 times of diabetes [ICD-9: 250.XX] diagnosis.

11 Research Design and Methods We designed a prospective cohort, consisting of hypoglycemic type 2 diabetes patients with randomly selected and age, sex, diabetes duration matched cases without hypoglycemia. Severe hypoglycemia Diabetic patients with hypoglycemia [ICD-9-CM: 251.2X] identified from the hospital claims dataset. Mild hypoglycemia Diabetic patients with hypoglycemia identified from the outpatient claims dataset.

12 Research Design and Methods We investigated the relations of hypoglycemia to total mortality, and cardiovascular events including stroke, coronary heart disease, cardiovascular diseases (CVD) and hospitalization from all causes.

13 Flow chart of study population 77,611 diabetic patients ( 3 times diabetes diagnosis) from the 1 million insured individuals who were newly diagnosed during ,000 DM without hypoglycemia were matched to 500 DM with hypoglycemia with regard to age, gender and duration of DM 500 DM with hypoglycemia were identified by hospital claims dataset 1,344 DM with hypoglycemia were identified by outpatient claims dataset 5,376 DM without hypoglycemia were matched to 1,344 DM with hypoglycemia with regard to age, gender and duration of DM Stroke, coronary heart disease, cardiovascular events and total mortality

14 Characteristics of Diabetic Patients with Hypoglycemia and Matches without Hypoglycemia (1) Severe Hypoglycemia (n = 500) No Hypoglycemia (n = 2,000) p-value Mild Hypoglycemia (n = 1,344) No Hypoglycemia (n = 5,376) p-value Age, yrs 65.2 ± ± ± ± Male sex % % % % Duration, yrs 3.75 ± ± ± ± Hypertension % % < % % < Atrial fibrillation % % % % Dyslipidemia % % % % < Liver cirrhosis % % % % Renal disease % % < % % < Stroke % % < % % < Heart disease % % < % % < Other drugs: other oral diabetic medications; Good compliance of treatment: Proportion of Days Covered (PDC) more than 80 percentage High social economic status: the insured salary more than median (16500 new Taiwan dollars)

15 Characteristics of Diabetic Patients with Hypoglycemia and Matches without Hypoglycemia (2) Severe Hypoglycemia (n = 500) No Hypoglycemia (n = 2,000) p-value Mild Hypoglycemia (n = 1,344) No Hypoglycemia (n = 5,376) p-value Mental disease % % < % % < Cancer % % < % % < High social economic status Good compliance % % % % % % % % < Insulin % % < % % < Sulfonylureas % % < % % < Other drugs % % < % % < High social economic status: the insured salary more than median (16500 new Taiwan dollars) Good compliance of treatment: Proportion of Days Covered (PDC) more than 80 percentage Other drugs: other oral diabetic medications;

16 Association between hypoglycemia and hospitalization caused by stroke, coronary heart disease, cardiovascular diseases and all-causes mortality in multivariate model Stroke CHD CVD Death Variables HR (95% C.I.) HR (95% C.I.) HR (95% C.I.) HR (95% C.I.) Mild hypoglycemia 1.92 ( ) 1.76 ( ) 2.21 ( ) 2.70 ( ) Severe hypoglycemia 1.64 ( ) 1.63 ( ) 2.26 ( ) 2.18 ( ) Adjusted for hypertension, atrial fibrillation, dyslipidemia, liver cirrhosis, renal, mental disease, cancer, previous stroke, heart disease, social economic status, drug compliance, and insulin, sulfonylurea uses.

17 Propensity Score Matched Analysis for Cardiovascular Diseases and Hospitalization Hypoglycemia (n=257) No Hypoglycemia (n=257) Cardiovascular diseases Event rate, per 1000 PYs HR (95% CI) 2.09 ( ) Reference Any cause hospitalization Event rate, per 1000 PYs HR (95% CI) 2.51 ( ) Reference Total mortality Event rate, per 1000 PYs HR (95% CI) 2.48 ( ) Reference After PS matched age, sex, DM duration, hypertension, Af, dyslipidemia, liver, renal, mental disease, previous stroke, heart disease, social economic status, and drug compliance.

18 Survival rate Association Between Hypoglycemia and Hospitalization From Any Cause P<0.001 None Mild Severe Years

19 (A) Hypoglycemia and stroke P< (B) Hypoglycemia and CHD P<0.001 Survival Survival None Mild Severe (C) Hypoglycemia and CVD (D) Hypoglycemia and total mortality 1.0 P< P< Survival Survival Time Time

20 Conclusions Hypoglycemic episodes in outpatient clinically treated type 2 DM patients, both mild and severe are strongly associated with subsequent major cardiovascular events, including stroke, CHD, and CVD, any causes of hospitalization and even allcause mortality. Diabetes patients who are vulnerable to hypoglycemia have more comorbidities including hypertension, liver disease, renal disease, mental disease, cancer and previous stroke or heart diseases.

21 Conclusions Medications, including insulin, and sulfonylurea are also important factors that promote hypoglycemic episodes. Once outpatient-treated diabetes patients have hypoglycemic episodes, cardiovascular and hospitalization events occur most frequently in the first year after the event regardless of whether the hypoglycemia was mild or severe.

22 Acknowledgement Taiwan Society of Cardiology Co-authors Shih-Hsien Sung, Hao-Min Cheng, Jong-Shiuan Yeh Wen-Ling Liu Wan-Leong Chan Chen-Huan Chen, Pesus Chou

ACCEPTED VERSION by the American Diabetes Association. Published version available at:

ACCEPTED VERSION by the American Diabetes Association. Published version available at: ACCEPTED VERSION Hsu, Pai-Feng; Sung, Shih-Hsien; Cheng, Hao-Min; Yeh, Jong-Shiuan; Liu, Wen-Ling; Chan, Wan-Leong; Chen, Chen-Huan; Chou, Pesus; Chuang, Shao-Yuan Association of clinical symptomatic hypoglycemia

More information

ADVANCE post trial ObservatioNal Study

ADVANCE post trial ObservatioNal Study Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute

More information

Supplementary webappendix

Supplementary webappendix Supplementary webappendix This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Ray K K, Seshasai S R K, Wijesuriya S,

More information

Glycemic control a matter of life and death

Glycemic control a matter of life and death Glycemic control a matter of life and death Linda Garcia Mellbin MD PhD Specialist in Cardiology & Internal medicine Dep of Cardiology Karolinska University Hospital /Karolinska Institutet Mortality (%)

More information

The Diabetes Link to Heart Disease

The Diabetes Link to Heart Disease The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM

More information

Supplementary Text A. Full search strategy for each of the searched databases

Supplementary Text A. Full search strategy for each of the searched databases Supplementary Text A. Full search strategy for each of the searched databases MEDLINE: ( diabetes mellitus, type 2 [MeSH Terms] OR type 2 diabetes mellitus [All Fields]) AND ( hypoglycemia [MeSH Terms]

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix Increased Risk of Atrial Fibrillation and Thromboembolism in Patients with Severe Psoriasis: a Nationwide Population-based Study Tae-Min Rhee, MD 1, Ji Hyun Lee, MD 2, Eue-Keun Choi,

More information

LATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?

LATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines? LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating

More information

CONTROLLO GLICEMICO E RISCHIO CARDIOVASCOLARE. AGOSTINO CONSOLI DMSI - Università d Annunzio CHIETI ITALY. sul Paziente ad alto rischio CV*

CONTROLLO GLICEMICO E RISCHIO CARDIOVASCOLARE. AGOSTINO CONSOLI DMSI - Università d Annunzio CHIETI ITALY. sul Paziente ad alto rischio CV* CONTROLLO GLICEMICO E RISCHIO CARDIOVASCOLARE AGOSTINO CONSOLI DMSI - Università d Annunzio CHIETI ITALY sul Paziente ad alto rischio CV* Does reducing hyperglycemia protect against cardiovascular risk?

More information

Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?

Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of

More information

Diabete: terapia nei pazienti a rischio cardiovascolare

Diabete: terapia nei pazienti a rischio cardiovascolare Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population

More information

ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES

ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A

More information

Supplement materials:

Supplement materials: Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction

More information

Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy

Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline

More information

The University of Mississippi School of Pharmacy

The University of Mississippi School of Pharmacy LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Lokhandwala T. MS, Yang Y. PhD, Thumula V. MS, Bentley J.P.

More information

The Clinical Unmet need in the patient with Diabetes and ACS

The Clinical Unmet need in the patient with Diabetes and ACS The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge

More information

Why is Earlier and More Aggressive Treatment of T2 Diabetes Better?

Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:

More information

Diabetes Mellitus: A Cardiovascular Disease

Diabetes Mellitus: A Cardiovascular Disease Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular

More information

Declaration of conflict of interest. None to declare

Declaration of conflict of interest. None to declare Declaration of conflict of interest None to declare Risk management of coronary artery disease Arrhythmias and diabetes Hercules Mavrakis Cardiology Department Heraklion University Hospital Crete, Greece

More information

Glucose and CV disease

Glucose and CV disease Glucose and CV disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,

More information

Metformin. Sulfonylurea. Thiazolidinedione. Insulin

Metformin. Sulfonylurea. Thiazolidinedione. Insulin 동아의대내분비내과박미경 Metformin Sulfonylurea Thiazolidinedione Insulin 요약 markers of inflammation (hs-crp, TNF-a) markers of impaired endothelial function (VFW, scams, tpa, PAI-1) LDL-C, fasting and postprandial

More information

JAMA. 2011;305(24): Nora A. Kalagi, MSc

JAMA. 2011;305(24): Nora A. Kalagi, MSc JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for

More information

Jacqueline C. Barrientos, Nicole Meyer, Xue Song, Kanti R. Rai ASH Annual Meeting Abstracts 2015:3301

Jacqueline C. Barrientos, Nicole Meyer, Xue Song, Kanti R. Rai ASH Annual Meeting Abstracts 2015:3301 Characterization of atrial fibrillation and bleeding risk factors in patients with CLL: A population-based retrospective cohort study of administrative medical claims data in the U.S. Jacqueline C. Barrientos,

More information

Chapter 2: Identification and Care of Patients With Chronic Kidney Disease

Chapter 2: Identification and Care of Patients With Chronic Kidney Disease Chapter 2: Identification and Care of Patients With Chronic Kidney Disease Introduction The examination of care in patients with chronic kidney disease (CKD) is a significant challenge, as most large datasets

More information

egfr > 50 (n = 13,916)

egfr > 50 (n = 13,916) Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according

More information

Update on CVD and Microvascular Complications in T2D

Update on CVD and Microvascular Complications in T2D Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine

More information

What s the Goal? Individualizing Glycemic Targets. Matthew Freeby M.D. December 3 rd, 2016

What s the Goal? Individualizing Glycemic Targets. Matthew Freeby M.D. December 3 rd, 2016 What s the Goal? Individualizing Glycemic Targets Matthew Freeby M.D. December 3 rd, 2016 Diabetes Mellitus: Complications and Co-Morbid Conditions Retinopathy Between 2005-2008, 28.5% of patients with

More information

USRDS UNITED STATES RENAL DATA SYSTEM

USRDS UNITED STATES RENAL DATA SYSTEM USRDS UNITED STATES RENAL DATA SYSTEM Chapter 2: Identification and Care of Patients With CKD Over half of patients from the Medicare 5 percent sample have either a diagnosis of chronic kidney disease

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Lin Y-S, Chen Y-L, Chen T-H, et al. Comparison of Clinical Outcomes Among Patients With Atrial Fibrillation or Atrial Flutter Stratified by CHA 2 DS 2 -VASc Score. JAMA Netw

More information

Macrovascular Disease in Diabetes

Macrovascular Disease in Diabetes Macrovascular Disease in Diabetes William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research Conflicts CPC Clinical Research (University-based

More information

Definitions of chronic conditions used to define the number of serious comorbidities in the study.

Definitions of chronic conditions used to define the number of serious comorbidities in the study. Supplementary Table 1 Definitions of chronic conditions used to define the number of serious comorbidities in the study. Comorbidity ICD-9 Code Description CAD/MI 410.x Acute myocardial infarction 411.x

More information

ACCORD, ADVANCE & VADT. Now what do I do in my practice?

ACCORD, ADVANCE & VADT. Now what do I do in my practice? ACCORD, ADVANCE & VADT Now what do I do in my practice? Richard M. Bergenstal, MD International Diabetes Center Park Nicollet Health Services University of Minnesota Minneapolis, MN richard.bergenstal@parknicollet.com

More information

Diabetes and the Heart

Diabetes and the Heart Diabetes and the Heart Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 6, 2012 Outline Screening for diabetes in patients with CAD Screening for CAD in patients with

More information

Glucose Control: Does it lower CV risk?

Glucose Control: Does it lower CV risk? Glucose Control: Does it lower CV risk? Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,

More information

Hanyang University Guri Hospital Chang Beom Lee

Hanyang University Guri Hospital Chang Beom Lee Hanyang University Guri Hospital Chang Beom Lee Meal prayer, Van Brekelenkam 17 th C Introduction 2012 ADA/EASD Position Statement Proper Patients for Pioglitazone β-cell Preservation by Pioglitazone Benefit

More information

Prevention of complications: are we winning or losing the battle. Naveed Sattar Professor of Metabolic Medicine

Prevention of complications: are we winning or losing the battle. Naveed Sattar Professor of Metabolic Medicine Prevention of complications: are we winning or losing the battle Naveed Sattar Professor of Metabolic Medicine Duality of Interest Declaration Consultant or speaker for: Amgen, AstraZeneca, Boehringer

More information

Adjunct Lecturer. National Yang-Ming University, Taiwan. Taipei Veterans General Hospital, Taiwan

Adjunct Lecturer. National Yang-Ming University, Taiwan. Taipei Veterans General Hospital, Taiwan Kuan-Po Peng MD Adjunct Lecturer National Yang-Ming University, Taiwan Taipei Veterans General Hospital, Taiwan Nothing to declare Disclosure Experience from the Taiwan National Health Insurance Research

More information

Glucose Control and Prevention of Cardiovascular Disease

Glucose Control and Prevention of Cardiovascular Disease Glucose Control and Prevention of Cardiovascular Disease Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Diabetes Update+, March

More information

Kidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)

Kidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain) Kidney and heart: dangerous liaisons Luis M. RUILOPE (Madrid, Spain) Type 2 diabetes and renal disease: impact on cardiovascular outcomes The "heavyweights" of modifiable CVD risk factors Hypertension

More information

A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular

More information

The earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College

The earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College The earlier BP control the better cardiovascular outcome Jin Oh Na Cardiovascular center Korea University Medical College Index Introduction HOPE-3 Trial Sprint Study Summary Each 2 mmhg decrease in SBP

More information

Diabetes new challenges, new agents, new order

Diabetes new challenges, new agents, new order Diabetes new challenges, new agents, new order Ken Earle St Georges University Hospitals NHS Foundation Trust Overview Cardiovascular disease unmet needs Treating evident and residual risk Integrating

More information

DIABETES AND METABOLIC SYNDROME

DIABETES AND METABOLIC SYNDROME TRIALS NUMBER OF PARTICIPANTS NUMBER OF WOMEN PERCENTAGE OF WOMEN MEAN AGE MEAN - (YEARS) TRIALS WITH ANALYSIS BY GENDER N, (%) 48,508 20,091 41.4% 61.1 4.3 4/7 (57.1%) HR PROactive (Dormandy et al 61

More information

Relative Risk of Major Risk of Chronic Major Disease Catego ries, by Gender and Gender and verag e Drinkin e Dr g Catego Females Males Disease Disea

Relative Risk of Major Risk of Chronic Major Disease Catego ries, by Gender and Gender and verag e Drinkin e Dr g Catego Females Males Disease Disea 38 th IMAG Conference, Amsterdam, October 13-14, 14, 2014 International Meeting on Alcohol and Global Health Overview: All-Cause Mortality Wolfgang Koenig MD, FRCP, FESC, FACC, FAHA Dept. of Internal Medicine

More information

Race Original cohort Clean cohort HR 95%CI P HR 95%CI P. <8.5 White Black

Race Original cohort Clean cohort HR 95%CI P HR 95%CI P. <8.5 White Black Appendix Table 1: Hazard Ratios of the association between CSCs and all-cause mortality from original cohort and the clean cohort excluding CHD/strokes. CSC categories Race Original cohort Clean cohort

More information

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System

More information

SUPPLEMENTAL MATERIALS

SUPPLEMENTAL MATERIALS SUPPLEMENTAL MATERIALS Table S1: Variables included in the propensity-score matching Table S1.1: Components of the CHA 2DS 2Vasc score Table S2: Crude event rates in the compared AF patient cohorts Table

More information

UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES

UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES Claudia Bucci BScPhm, PharmD Clinical Coordinator, Cardiovascular Diseases Sunnybrook Health Sciences Centre 21st Annual Contemporary Therapeutic Issues in

More information

Dapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58

Dapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58 Dapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58 Marc P. Bonaca MD MPH for the DECLARE TIMI 58 Investigators American College of Cardiology March 2019

More information

Approach to Dyslipidemia among diabetic patients

Approach to Dyslipidemia among diabetic patients Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences

More information

Diabetes and Hypertension

Diabetes and Hypertension Diabetes and Hypertension William C. Cushman, MD, FAHA, FACP, FASH Chief, Preventive Medicine, Veterans Affairs Medical Center Professor, Preventive Medicine, Medicine, and Physiology University of Tennessee

More information

Chapter 4: Cardiovascular Disease in Patients With CKD

Chapter 4: Cardiovascular Disease in Patients With CKD Chapter 4: Cardiovascular Disease in Patients With CKD Introduction Cardiovascular disease is an important comorbidity for patients with chronic kidney disease (CKD). CKD patients are at high-risk for

More information

Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center

Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes

More information

Complications of Diabetes: Screening and Prevention

Complications of Diabetes: Screening and Prevention Complications of Diabetes: Screening and Prevention Dr Steve Cleland Consultant Physician GGH and QEUH Diabetes Staff Education Course June 17 Diabetic Complications Microvascular: Retinopathy Nephropathy

More information

Cedars Sinai Diabetes. Michael A. Weber

Cedars Sinai Diabetes. Michael A. Weber Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor

More information

Causes of death in Diabetes

Causes of death in Diabetes Rates of CV events in Diabetes patients Respiratory4.2 Cancer 7.6 Diabetes 1.3 CV disease 17.3 Causes of death in Diabetes 250 200 150 100 50 0 per 10,000 person-years 97 151 243 Framingham 5 X increase

More information

T. Suithichaiyakul Cardiomed Chula

T. Suithichaiyakul Cardiomed Chula T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial

More information

Comorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care AF symptoms Tachycardia

Comorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care AF symptoms Tachycardia Supplementary Table S1 International Classification of Disease 10 (ICD-10) codes Comorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care I48 AF

More information

Blood Pressure Targets in Diabetes

Blood Pressure Targets in Diabetes Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet

More information

Hyperuricemia Cannot Additionally Predict Cardiac or Total Death in

Hyperuricemia Cannot Additionally Predict Cardiac or Total Death in Original Article Hyperuricemia Cannot Additionally Predict Cardiac or Total Death in Acta General Cardiol Population Sin 2012;28:225 235 General Cardiology Adding Hyperuricemia to Traditional Cardiac Risk

More information

The Correlation of Patients with Spinal Cord Injury and Psychiatric Disorders. Ching Hui, Chuang Chung Hey, Chen

The Correlation of Patients with Spinal Cord Injury and Psychiatric Disorders. Ching Hui, Chuang Chung Hey, Chen The Correlation of Patients with Spinal Cord Injury and Psychiatric Disorders Ching Hui, Chuang Chung Hey, Chen Introduction Spinal cord injury (SCI) is a common devastating accident in modern society.

More information

Cost Effectiveness of Linagliptin versus Sulfonylurea as An Add-on Therapy to Metformin in Patients with Type 2 Diabetes Mellitus

Cost Effectiveness of Linagliptin versus Sulfonylurea as An Add-on Therapy to Metformin in Patients with Type 2 Diabetes Mellitus Curriculum vitae Nama : Dr. Dra. Erna Kristin, MSi, Apt Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, Indonesia. Apothecaries Degree Gadjah Mada University, Master degree Gadjah Mada University,

More information

Is Lower Better for LDL or is there a Sweet Spot

Is Lower Better for LDL or is there a Sweet Spot Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,

More information

Rikshospitalet, University of Oslo

Rikshospitalet, University of Oslo Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular

More information

IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS

IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes

More information

Mortality following acute myocardial infarction (AMI) in

Mortality following acute myocardial infarction (AMI) in In-Hospital Mortality Among Patients With Type 2 Diabetes Mellitus and Acute Myocardial Infarction: Results From the National Inpatient Sample, 2000 2010 Bina Ahmed, MD; Herbert T. Davis, PhD; Warren K.

More information

SESSION 3 11 AM 12:30 PM

SESSION 3 11 AM 12:30 PM SESSION 3 11 AM 12:30 PM for the Primary Prevention of Cardiovascular Disease: A Personalized Approach SPEAKER Samia Mora MD, MHS Presenter Disclosure Information The following relationships exist related

More information

Research Article Risk Factors for Chronic Subdural Hematoma after a Minor Head Injury in the Elderly: A Population-Based Study

Research Article Risk Factors for Chronic Subdural Hematoma after a Minor Head Injury in the Elderly: A Population-Based Study BioMed Research International, Article ID 218646, 6 pages http://dx.doi.org/10.1155/2014/218646 Research Article Risk Factors for Chronic Subdural Hematoma after a Minor Head Injury in the Elderly: A Population-Based

More information

Microvascular Disease in Type 1 Diabetes

Microvascular Disease in Type 1 Diabetes Microvascular Disease in Type 1 Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine The Course

More information

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital 1. Importance of Lowering LDL-Cholesterol in Diabetes Patients & Lipid Guidelines Prevalence of dyslipidemia in Korea Prevalence

More information

Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study

Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Conflict of interest disclosure None Committee of Scientific Affairs Committee

More information

CLINICAL PROCESS IMPROVEMENT INITIATIVE (CPII) EFFICIENCY REPORT EXPLANATION January 4, 2016

CLINICAL PROCESS IMPROVEMENT INITIATIVE (CPII) EFFICIENCY REPORT EXPLANATION January 4, 2016 CLINICAL PROCESS IMPROVEMENT INITIATIVE (CPII) EFFICIENCY REPORT EXPLANATION January 4, 2016 WHAT IS AN EPISODE OF CARE? An episode of care is a grouping of a patient s health care claims for a unique

More information

The presenter does not have any potential conflicts of interest to disclose

The presenter does not have any potential conflicts of interest to disclose Carotid intima-media thickness as a predictor of multi territory atherosclerotic occlusive disease in patients with symptomatic subclavian artery obstruction Leszek Wrotniak 1, Anna Kabłak Ziembicka 1,

More information

Table S1: Diagnosis and Procedure Codes Used to Ascertain Incident Hip Fracture

Table S1: Diagnosis and Procedure Codes Used to Ascertain Incident Hip Fracture Technical Appendix Table S1: Diagnosis and Procedure Codes Used to Ascertain Incident Hip Fracture and Associated Surgical Treatment ICD 9 Code Descriptions Hip Fracture 820.XX Fracture neck of femur 821.XX

More information

Fasting or non fasting?

Fasting or non fasting? Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues

More information

State of art in anticoagulation in non valvular Atrial Fibrillation: the additional value of Rivaroxaban real life data

State of art in anticoagulation in non valvular Atrial Fibrillation: the additional value of Rivaroxaban real life data State of art in anticoagulation in non valvular Atrial Fibrillation: the additional value of Rivaroxaban real life data Massimo Grimaldi Ospedale F. Miulli Acquaviva delle Fonti - Bari Disclosure Biosense

More information

Old oral antidiabetic agents in the armamentarium of diabetes mellitus treatment: Safety and efficacy

Old oral antidiabetic agents in the armamentarium of diabetes mellitus treatment: Safety and efficacy Old oral antidiabetic agents in the armamentarium of diabetes mellitus treatment: Safety and efficacy Melpomeni Peppa Assistant Professor of Endocrinology 2 nd Dept of Internal Medicine-Propaedeutic, Athens

More information

USRDS UNITED STATES RENAL DATA SYSTEM

USRDS UNITED STATES RENAL DATA SYSTEM USRDS UNITED STATES RENAL DATA SYSTEM Chapter 9: Cardiovascular Disease in Patients With ESRD Cardiovascular disease is common in ESRD patients, with atherosclerotic heart disease and congestive heart

More information

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories

More information

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant

More information

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention

More information

Diabetes Mellitus: Implications of New Clinical Trials and New Medications

Diabetes Mellitus: Implications of New Clinical Trials and New Medications Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October

More information

Investor Conference Call

Investor Conference Call Investor Conference Call Data from the Phase III COMPASS trial, A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery

More information

Antiplatelet agents treatment

Antiplatelet agents treatment Session III Comprehensive management of diabetic patients Antiplatelet agents treatment Chonnam National University Hospital Department of Internal Medicine Dong-Hyeok Cho CONTENTS Introduction Prothrombotic

More information

SCIENTIFIC STUDY REPORT

SCIENTIFIC STUDY REPORT PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established

More information

Fixed dose combination for Trusted Diabetes Control Lobna Farag Eltooy Head of Internal Medicine Department Assiut University

Fixed dose combination for Trusted Diabetes Control Lobna Farag Eltooy Head of Internal Medicine Department Assiut University Fixed dose combination for Trusted Diabetes Control By Lobna Farag Eltooy Head of Internal Medicine Department 1 Assiut University 3/18/2018 3/18/2018 3/18/2018 Diabetes Complications with Increasing HbA1c

More information

CVD risk assessment using risk scores in primary and secondary prevention

CVD risk assessment using risk scores in primary and secondary prevention CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities

More information

Effect of SGLT-2 Inhibitors on the Heart. Robert Zimmerman MD Vice Chairman Endocrinology Director Diabetes Center Cleveland Clinic

Effect of SGLT-2 Inhibitors on the Heart. Robert Zimmerman MD Vice Chairman Endocrinology Director Diabetes Center Cleveland Clinic Effect of SGLT-2 Inhibitors on the Heart Robert Zimmerman MD Vice Chairman Endocrinology Director Diabetes Center Cleveland Clinic Disclosures Speaker - Johnson and Johnson - Merck Research - Merck - Novo

More information

D:A:D Study Teaching Material

D:A:D Study Teaching Material D:A:D Study Teaching Material Data Collection of Adverse events of anti-hiv Drugs (D:A:D) study December 2012 - CHIP Background The D:A:D Study, is a prospective cohort study (collaboration) initiated

More information

Diabetes and the heart: mechanisms of cardiac injury, hypertension and heart failure. SAGLB.DIA u Date of approval: November 2017

Diabetes and the heart: mechanisms of cardiac injury, hypertension and heart failure. SAGLB.DIA u Date of approval: November 2017 Diabetes and the heart: mechanisms of cardiac injury, hypertension and heart failure SAGLB.DIA.17.08.0968u Date of approval: November 2017 Abbreviations ACS: acute coronary syndrome AGE: advanced glycoxidation

More information

SUPPLEMENTARY DATA. Supplementary Figure S1. Cohort definition flow chart.

SUPPLEMENTARY DATA. Supplementary Figure S1. Cohort definition flow chart. Supplementary Figure S1. Cohort definition flow chart. Supplementary Table S1. Baseline characteristics of study population grouped according to having developed incident CKD during the follow-up or not

More information

Heart Failure and COPD: Common Partners, Common Problems. Nat Hawkins Liverpool Heart and Chest Hospital

Heart Failure and COPD: Common Partners, Common Problems. Nat Hawkins Liverpool Heart and Chest Hospital Heart Failure and COPD: Common Partners, Common Problems Nat Hawkins Liverpool Heart and Chest Hospital Disclosures: No conflicts of interest Common partners, common problems COPD in HF common partners

More information

Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre

Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre Outline How big is the problem? Natural progression of type 2 diabetes What

More information

CARDIOVASCULAR EVENTS IN POLYCYSTIC OVARY SYNDROME

CARDIOVASCULAR EVENTS IN POLYCYSTIC OVARY SYNDROME CARDIOVASCULAR EVENTS IN POLYCYSTIC OVARY SYNDROME Enrico Carmina Executive Director & CEO of Androgen Excess & PCOS Society Professor of Endocrinology Department of Health Sciences and Mother and Child

More information

Supplementary Information. Statins Improve Long Term Patency of Arteriovenous Fistula for

Supplementary Information. Statins Improve Long Term Patency of Arteriovenous Fistula for Supplementary Information Statins Improve Long Term Patency of Arteriovenous Fistula for Hemodialysis Hao-Hsiang Chang MD, MSc 1,2, Yu-Kang Chang PhD 3, Chia-Wen Lu MD 1, Chi-Ting Huang 3, Chiang-Ting

More information

Management of cardiovascular disease. Acute coronary syndromes and intensive care. Lars Rydén Karolinska Institutet Stockholm, Sweden

Management of cardiovascular disease. Acute coronary syndromes and intensive care. Lars Rydén Karolinska Institutet Stockholm, Sweden Management of cardiovascular disease Acute coronary syndromes and intensive care Lars Rydén Karolinska Institutet Stockholm, Sweden Hyperglycemia and acute coronary syndromes Changing fenotype GAMI Study

More information

Blood Pressure Targets: Where are We Now?

Blood Pressure Targets: Where are We Now? Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy

More information

Dr Kerry Gunn. Dr Nicola Broadbent. Anaesthesiologist Auckland City Hospital Auckland. Specialist Anaesthetist Auckland City Hospital Auckland

Dr Kerry Gunn. Dr Nicola Broadbent. Anaesthesiologist Auckland City Hospital Auckland. Specialist Anaesthetist Auckland City Hospital Auckland Dr Kerry Gunn Anaesthesiologist Auckland City Hospital Auckland Dr Nicola Broadbent Specialist Anaesthetist Auckland City Hospital Auckland 8:30-9:25 WS #96: Optimising Patients for Surgery - Defining

More information

Polypharmacy - arrhythmic risks in patients with heart failure

Polypharmacy - arrhythmic risks in patients with heart failure Influencing sudden cardiac death by pharmacotherapy Polypharmacy - arrhythmic risks in patients with heart failure Professor Dan Atar Head, Dept. of Cardiology Oslo University Hospital Ullevål Norway 27.8.2012

More information

Institute of Medical Epidemiology, Biostatistics, and Informatics, University of Halle-Wittenberg, Halle (Saale) 2

Institute of Medical Epidemiology, Biostatistics, and Informatics, University of Halle-Wittenberg, Halle (Saale) 2 Do Randomized and Non-Randomized Trials Yield Different Answers in Similar Populations? Evidence from a 'Meta-Propensity Score' Analysis in Cardiac Surgery Kuss O 1, Legler T 1, Börgermann J 2 1 Institute

More information